CHC

Biological Activity

Monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide (Cat No. 2706). Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study.
   Colen et al.
   Neurosurgery, 2006;59:1313
2. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.
   Miranda-Gonçalves et al.
   Neuro.Oncol., 2013;15:172
3. The H⁺-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma.
   Fang et al.
   Mol.Pharmacol., 2006;70:2108
4. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells.
   Dimmer et al.
   Biochem.J., 2000;350:219

Product Datasheets